📇 Rhumatologue · PARIS CEDEX 13 · (75) · Mixte
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
11 articles scientifiques publiés — formation continue solide
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
24
24 articles ont été cités au moins 24fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
3 238
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
54
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
29
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Sorbonne Université · Pitié-Salpêtrière Hospital
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era
2021ArticleClinics and Research in Hepatology and Gastroenterology
Recalibrated MELD and hepatic encephalopathy are prognostic factors in cirrhotic patients with acute variceal bleeding
2018ArticleLiver International
Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding
2015ArticleHepatology
Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial
2008ArticleHepatology
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
2006ArticleThe American Journal of Gastroenterology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP SUN SITE PITIE SALPETRIERE
47-83 47 BD DE L HOPITAL, 75651 PARIS CEDEX 13
CABINET DU DR JULIEN MASSARD
TOUR ATLAS 10 VILLA D ESTE, 75013 PARIS
CABINET DU DR JULIEN MASSARD
CLINIQUE JEANNE D'ARC 11 RUE PONSCARME, 75013 PARIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
BMC gastroenterology · 2006
Abstract Background Liver biopsy is considered as the gold standard for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions. The aim of this study was to determine the diagnostic utility of non-invasive markers of fibrosis, validated in chronic viral hepatitis and alcoholic liver disease (FibroTest, FT), in patients with NAFLD. Methods 170 patients with suspected NAFLD were prospectively included in a reference center (Group 1), 97 in a multicenter study (Group 2) and 954 blood donors as controls. Fibrosis was assessed on a 5 stage histological scale validated by Kleiner et al from F0 = none, F1 = perisinusoidal or periportal, F2 = perisinusoidal and portal/periportal, F3 = bridging and F4 = cirrhosis. Histology and the biochemical measurements were blinded to any other characteristics. The area under the ROC curves (AUROC), sensitivity (Se), specificity (Sp), positive and negative predictive values (PPV, NPV) were assessed. Results In both groups FT has elevated and not different AUROCs for the diagnosis of advanced fibrosis (F2F3F4): 0.86 (95%CI 0.77–0.91) versus 0.75 (95%CI 0.61–0.83; P = 0.10), and for F3F4: 0.92 (95%CI 0.83–0.96) versus 0.81 (95%CI 0.64–0.91; P = 0.12) in Group1 and Group 2 respectively. When the 2 groups were pooled together a FT cutoff of 0.30 had a 90% NPV for advanced fibrosis (Se 77%); a FT cutoff of 0.70 had a 73% PPV for advanced fibrosis (Sp 98%). Conclusion In patients with NAFLD, FibroTest, a simple and non-invasive quantitative estimate of liver fibrosis reliably predicts advanced fibrosis.
Hepatology (Baltimore, Md.) · 2007
Although it is often functional at presentation, acute renal failure has a poor prognosis in patients with cirrhosis. The role of inflammation, a key event in the outcome of cirrhosis, has never been studied in this setting. We aimed to investigate the predictive factors of mortality in patients with cirrhosis and acute functional renal failure, specifically in relation to inflammatory events. One hundred consecutive patients with cirrhosis from 5 French hospitals were prospectively included at the day of onset of acute renal failure. Medical history, treatments, and procedures during the month before inclusion were recorded. Physical examination, blood and urinary chemistries, and renal ultrasound examination were performed. The presence of systemic inflammatory response syndrome (SIRS), infection, and sepsis was assessed. The primary outcome was in-hospital mortality. The mechanism of renal failure was functional in 83 patients. Causes of renal failure were hypovolemia (34%), hepatorenal syndrome without ongoing infection (17%), hepatorenal syndrome with ongoing infection (16%), nephrotoxicity (2%), and multifactorial (31%). SIRS was observed in 41% of patients, 56% of them with infection. In-hospital mortality was 68% in patients with SIRS and 33% in patients without ( P = 0.001). In multivariate analysis, only model for end-stage liver disease score and presence of SIRS, but not infection, remained associated with a poor outcome. Conclusion: The presence of SIRS, with or without infection, is a major independent prognostic factor in patients with cirrhosis and acute functional renal failure. This suggests that preventing and treating SIRS could decrease mortality in patients with cirrhosis and acute renal failure. (Hepatology 2007.)
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Terapevticheskii arkhiv · 2013 · Journal Article
Kochetkova EA, Ugaĭ LG, Nevzorova VA, Massard J
Hepatology (Baltimore, Md.) · 2007 · Clinical Trial
Thabut D, Massard J, Gangloff A, Carbonell N, et al.
BMC gastroenterology · 2006 · Journal Article
Poynard T, Ratziu V, Charlotte F, Messous D, et al.
The American journal of gastroenterology · 2006 · Comparative Study
Thabut D, Le Calvez S, Thibault V, Massard J, et al.
Journal of hepatology · 2006 · Evaluation Study
Thabut D, Naveau S, Charlotte F, Massard J, et al.
BMC gastroenterology · 2006 · Comparative Study
Ratziu V, Massard J, Charlotte F, Messous D, et al.
Journal of hepatology · 2006 · Journal Article
Massard J, Ratziu V, Thabut D, Moussalli J, et al.
BMC gastroenterology · 2007 · Case Reports
Prodanovic H, Cracco C, Massard J, Barrault C, et al.
BMC gastroenterology · 2010 · Comparative Study
Poynard T, Lebray P, Ingiliz P, Varaut A, et al.
Hepatology (Baltimore, Md.) · 2008 · Journal Article
Bosch J, Thabut D, Albillos A, Carbonell N, et al.
Antiviral therapy · 2010 · Journal Article
Poynard T, Ngo Y, Munteanu M, Thabut D, et al.
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease-7
<b>Copyright information:</b>Taken from "Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease"BMC Gastroenterology 2006
Value of the index Nash-NashTest designed for the diagnosis of NASH
<b>Copyright information:</b>Taken from "Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease"BMC Gastroenterology 2006
Notched box plots showing the relationship between the stage of fibrosis and FibroTest
<b>Copyright information:</b>Taken from "Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease"BMC Gastroenterology 2006;6()
ROC curves of the NashTest for the diagnosis of No NASH in Training and in Validation Groups
<b>Copyright information:</b>Taken from "Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease"BMC Gastroenterology 2006
ROC curves of the NashTest for the diagnosis of NASH in Training and in Validation Groups
<b>Copyright information:</b>Taken from "Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease"BMC Gastroenterology 2006
Notched box plots showing the relationship between the stage of fibrosis and FibroTest
<b>Copyright information:</b>Taken from "Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease"BMC Gastroenterology 2006;6()
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).